Lumanity notes that Novartis and Bristol Myers Squibb paused their CD19 CAR-T autoimmune trials.
Public source
Publisher name
Public post
Novartis and Bristol Myers Squibb just paused their CD19 #CAR-T autoimmune trials. Analysts seem to be pointing at manufacturing but I think that may be only part of the…
Company
Lumanity
We Engineer Breakthrough Value
- Industry
- Business Consulting and Services
- Location
- Morristown, US
- Company size
- 501–1,000 employees
About Lumanity
We are committed to cracking the code on the future of healthcare by revolutionizing how value is generated, demonstrated, and communicated to unlock the full potential of your brand and your company. Our unique perspectives and agile approach equip you to thrive in an ever-changing healthcare marketplace by accelerating and optimizing access to life-changing medicines.
See moreLatest activity
Latest activity from Lumanity
11 signals
Presence & Recognition
Lumanity's Moira Ringo, VP of Market Access Strategy, is speaking to APM Market Access in two feature articles on US drug pricing.
Products & Services
Lumanity introduced Lumanity Lens, a newsletter covering the full product lifecycle from clinical development through commercialization.
Presence & Recognition
Lumanity is hosting a CancerProgress webinar on November 10th as a follow-up to the June 2026 BIO panel featuring Adina P., Axel Hoos, Hans-Peter Gerber, and Johanna K. Kaufmann, plus Kaveri Pohlman, PhD, MBA.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
RxClarity
RxClarity reports that Autoimmune CAR-T faced a significant safety reset as Novartis and Bristol Myers Squibb paused programmes.
Legal & Regulatory
Boston Children's Hospital
Boston Children's Hospital noted that Novartis paused eight autoimmune and neurology trials of its CD19 CAR-T rap-cel on August 24 after three deaths from immune effector cell-associated hemophagocytic syndrome (IEC-HS).
Legal & Regulatory
Ionic
Ionic reported that several autoimmune CAR T cell trials from Novartis and Bristol Myers Squibb were halted due to adverse inflammatory immune related events, including several patient deaths.
Legal & Regulatory
Cellipont Bioservices
Cellipont Bioservices published a full article on the development of CAR-T therapies for autoimmune and neurological diseases, highlighting patient safety and clinical trials.
Legal & Regulatory
Robert Half